Top of page Skip navigation
MetaboMeeting
MetaboMeeting
MetaboMeeting

Next Generation Precision Metabolomics – The Clinical Frontier
Dr John Ryals, CEO and President of Metabolon Inc

Metabolon has developed an advanced metabolomic technology called Precision Metabolomics, which is providing unprecedented insight into biochemical pathways related to health and disease. In several collaborations, using large population studies, we have shown that by matching either SNP data, exome sequencing data or whole genome sequencing data to our measurements of the metabolome we can uncover the function of previously unknown genes. The majority of this work is done in humans where we have mapped over 100,000 people but the approach could be used equally to understand gene function in other organisms. When measuring metabolism with a global metabolomics approach we can essentially access the equivalent of hundreds of clinical laboratory tests. This has tremendous value in both understanding and assessing health and trajectories towards disease states. We have used our precision metabolomics approach to better understand the nature of inherited metabolic disorders and undiagnosed disease.